Monday, October 5, 2026

AI Cloud ETFs Sink Up to 22% as Stagflation Fears Cement Higher-for-Longer Rate Regime

WCLD, CLOD, and SKYY have lost between 10% and 22% year-to-date as a synchronized global central bank hold cycle crushes growth-stock valuations. IMF warnings of a 1970s-scale oil crisis and sticky inflation expectations are killing rate-cut hopes across the Fed, ECB, BoE, BoJ, and BoC. Fed Chair Powell's May 15 departure adds governance uncertainty at the worst possible moment for AI capital markets.

LM Salvado

April 27, 2026

AI Cloud ETFs Sink Up to 22% as Stagflation Fears Cement Higher-for-Longer Rate Regime
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

AI and cloud stocks are under sustained pressure. WCLD is down 22%, CLOD off 14%, and SKYY down 10% year-to-date as a synchronized central bank hold cycle locks in a higher-for-longer rate environment.

The driver is stagflation risk. IMF chief economist Pierre-Olivier Gourinchas warned the current oil shock "could rival that of the 1970s,"1 eliminating the conditions under which central banks would normally ease. Fed Chair Powell confirmed inflation expectations "have climbed since the start of the year,"2 reinforcing the case for holding rates at current levels.

The pressure is not confined to the US. Estonia's central bank, Eesti Pank, projects 3.8% inflation for 2026,3 illustrating how sticky price pressures are spreading across economies. The ECB faces the same bind. Governing Council member Alexander Demarco said "June is a better moment than April" to decide on any rate response to the Iran conflict,4 while fellow member Gediminas Simkus stated the ECB cannot rule out a rate hike later this year.5

The valuation math is straightforward. AI and cloud stocks trade on high earnings multiples tied to distant future cash flows. Elevated discount rates shrink those present values mechanically—even without any deterioration in underlying fundamentals. Strong revenue growth at hyperscalers is not enough to offset the multiple compression when rate-cut timelines keep extending.

The Fed's own leadership transition compounds the uncertainty. Chair Powell exits May 15. Kevin Warsh's nomination is now unblocked, but any change at the top of the Fed introduces policy ambiguity exactly when markets need a clear rate path to reprice growth assets.

Longer term, the stagflation scenario—slow growth alongside sticky inflation—is structurally hostile to AI investment cycles. Hyperscaler capital expenditure programs for GPU clusters and data center buildouts depend on accessible financing. A prolonged rate ceiling raises the cost of the debt that funds those buildouts, slowing the infrastructure expansion the AI sector has priced in.

Fintech incumbents face an added headwind. US regulatory action targeting credit-score pricing is compressing FICO's and TransUnion's margins. Tight monetary conditions leave both companies without a rate-relief buffer, a pattern likely to spread to other data-driven financial services businesses in the current environment.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· April 25, 2026
    3 Market Trends That Could Shape the Rest of 2026
  2. [2]News articleNasdaq· April 17, 2026
    Dollar Drops on Middle East Peace Optimism
  3. [3]News articleYahoo Finance· April 18, 2026
    Experts Warn That Recession Risks Are Increasing. Here's What That Means for Investors
  4. [4]Press releaseGlobeNewswire· April 21, 2026
    Liven AS - 2026. aasta I kvartali konsolideeritud auditeerimata vahearuanne
  5. [5]Press releaseGlobeNewswire· April 21, 2026
    Liven AS - Consolidated unaudited interim report for the I quarter of 2026
  6. [6]News articleNasdaq· April 17, 2026
    S&P 500 and Nasdaq 100 Soar to Record Highs as Middle East Tensions Ease
  7. [7]News articleNasdaq· April 17, 2026
    Stocks Rally as Iran Announces Strait of Hormuz is "Completely Open"
  8. [8]News articleNasdaq· April 22, 2026
    Stocks Settle Higher as Nasdaq Posts a Record High on Tech Strength
  9. [9]News articleNasdaq· April 17, 2026
    Stocks Soar on Middle East Peace Prospects
  10. [10]News articleNasdaq· April 25, 2026
    The Federal Reserve's Interest Rate Dilemma Is About to Go From Bad to Warsh -- and the Stock Market May End Up Paying the Price
  11. [11]News articleNasdaq· April 19, 2026
    The Recent CPI Report Is Already Shifting 2027 COLA Forecasts -- What Retirees Should Know
  12. [12]News articleYahoo Finance· April 25, 2026
    3 Cloud Computing ETFs to Buy as Enterprise AI Spending Accelerates in 2026

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com